ArticleScientific reports2025
Integration of single-cell and bulk RNA sequencing data to identify liquid-liquid phase separation-related prognostic biomarkers in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal analysis reveals potential association of CDH13 with endothelial cells and its overexpression in hepatocellular carcinoma.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid-liquid phase separation (LLPS) has been linked to the initiation and progression of cancers. This study aimed to investigate the LLPS-related molecular features and develop a prognostic signature for hepatocellular carcinoma (HCC). Single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq data were obtained from open-source repositories. The Seurat package was used for processing and analyzing scRNA-seq data. LLPS-related genes (LLPSRGs) were identified by integrating scRNA-seq and bulk RNA-seq data. Univariate Cox and LASSO regression analyses were employed to construct an LLPS-related prognostic risk model. A predictive nomogram was also developed based on the risk score and clinicopathologic features. Additionally, correlations between clinicopathological features, biological functions, and tumor mutations with prognostic risk were explored. Experimental validation included cell transfection, wound healing, and transwell assays. Fourteen distinct cell clusters were identified, with malignant hepatocytes exhibiting the highest LLPS score. High-LLPS hepatocytes strongly interacted with other cells, showing elevated expression of EGFR-ERGF, EGFR-AREG, MIF-CD44, and MIF-CXCR4 interactions. The LLPS score was associated with malignant differentiation of hepatocytes. Ten LLPSRGs were identified as part of the LLPS-related risk signature, and potential agents were predicted: Olitigaltin and Lactose for LGALS3, and Sitamaquine, Phenazopyridine, Sulfanilamide, Pamaquine, Sodium ascorbate, and Co-trimoxazole for G6PD. Knockdown of LGALS3 inhibited HCC cell migration and invasion. LLPS-related molecular characteristics were identified, and an LLPS-related prognostic model was developed, offering novel insights into HCC research and providing potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.